Progressive APOBEC3B mRNA expression in distant breast cancer metastases

Anieta M. Sieuwerts, Willemijne A.M.E. Schrijver, Simone U. Dalm, Vanja De Weerd, Cathy B. Moelans, Natalie Ter Hoeve, Paul J. Van Diest, John W.M. Martens, Carolien H.M. Van Deurzen

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: APOBEC3B was recently identified as a gain-of-function enzymatic source of mutagenesis, which may offer novel therapeutic options with molecules that specifically target this enzyme. In primary breast cancer, APOBEC3B mRNA is deregulated in a substantial proportion of cases and its expression is associated with poor prognosis. However, its expression in breast cancer metastases, which are the main causes of breast cancer-related death, remained to be elucidated. Patients and methods: RNA was isolated from 55 primary breast cancers and paired metastases, including regional lymph node (N = 20) and distant metastases (N = 35). APOBEC3B mRNA levels were measured by RT-qPCR. Expression levels of the primary tumors and corresponding metastases were compared, including subgroup analysis by estrogen receptor (ER/ESR1) status. Results: Overall, APOBEC3B mRNA levels of distant metastases were significantly higher as compared to the corresponding primary breast tumor (P = 0.0015), an effect that was not seen for loco-regional lymph node metastases (P = 0.23). Subgroup analysis by ER-status showed that increased APOBEC3B levels in distant metastases were restricted to metastases arising from ER-positive primary breast cancers (P = 0.002). However, regarding ERnegative primary tumors, only loco-regional lymph node metastases showed increased APOBEC3B expression when compared to the corresponding primary tumor (P = 0.028). Conclusion: APOBEC3B mRNA levels are significantly higher in breast cancer metastases as compared to the corresponding ER-positive primary tumors. This suggests a potential role for APOBEC3B in luminal breast cancer progression, and consequently, a promising role for anti-APOBEC3B therapies in advanced stages of this frequent form of breast cancer.

Original languageEnglish (US)
Article numbere0171343
JournalPloS one
Volume12
Issue number1
DOIs
StatePublished - Jan 2017

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Progressive APOBEC3B mRNA expression in distant breast cancer metastases'. Together they form a unique fingerprint.

Cite this